XLO Profile
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of advanced immunotherapies aimed at enhancing the immune system's ability to fight cancer. The company’s innovative approach involves creating therapies that specifically target and modulate the immune response to improve efficacy in treating cancer patients.
Central to Xilio's strategy is its checkpoint inhibitor program, which features XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody (mAb) currently in Phase 1/2 clinical trials. This therapy is designed to target and inhibit the CTLA-4 checkpoint, potentially allowing the immune system to more effectively recognize and attack solid tumors.
Additionally, Xilio is advancing several cytokine-based therapies, which include XTX202, a modified form of interleukin-2 (IL-2); XTX301, an interleukin-12 (IL-12) product candidate; and XTX401, an interleukin-15 (IL-15) product candidate. These cytokine programs utilize a unique masking technology that prevents the cytokines from binding to their targets until they are activated by tumor microenvironment-associated proteases. This approach aims to enhance the therapeutic efficacy while minimizing off-target effects.
Founded in 2016, Xilio Therapeutics is headquartered in Waltham, Massachusetts. The company is committed to advancing its pipeline of immunotherapeutic agents and is focused on delivering transformative therapies to improve patient outcomes in oncology.
|
